Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly evolving field of personalized cancer neoantigen vaccines and is utilizing its Vaccibody technology to generate first-in-class therapies for cancers with significant unmet medical needs. Additionally, the company focuses on infectious disease research.Based on a deep understanding of immunological principles, Vaccibody is developing cutting-edge targeted DNA vaccines for clinical use. Vaccibody’s vaccines are specifically designed to target antigen-presenting cells. Through intelligent design, Vaccibody vaccines can be customized to induce the desired immune response profile, correlating with protection against each specific disease targeting any particular antigen. The Vaccibody vaccine platform holds the potential to address many diseases with unmet medical needs, such as cancer and infectious diseases. Furthermore, Vaccibody has partnerships with Roche and Nektar Therapeutics. Vaccibody’s lead candidates include VB10.NEO (a personalized therapeutic cancer neoantigen vaccine currently being evaluated in Phase I/IIa clinical trials) and VB10.16 (a therapeutic cancer vaccine for HPV16-related cancers currently being tested in Phase II clinical trials).